| JNJ |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$2.93 vs. cons $2.86 |
MEDIUM |
| JNJ |
Report |
Total revenue (Q2'26) |
IN-LINE |
pred ~$25.15B vs. cons $25.03B |
MEDIUM |
| JNJ |
Report |
Innovative Medicine revenue (Q2'26) |
BEAT |
pred ~$16.35B vs. cons $16.1B |
MEDIUM |
| JNJ |
Guide |
FY2026 Adjusted EPS guide |
BETTER |
guide ~$11.60 vs. cons $11.55 (FY2026) |
MEDIUM |
| JNJ |
Guide |
FY2026 Reported sales guide |
BETTER |
guide ~$101.0B vs. cons $100.8B (FY2026) |
MEDIUM |
| JNJ |
Guide |
MedTech organic growth (Q2'26) |
LOWER |
guide ~+4.5% vs. cons +5.25% (Q2'26) |
MEDIUM |
| JNJ |
Guide |
2H MedTech/EP China VBP headwind commentary |
LOWER |
guide ~-100bps drag vs. cons ~0bps (2H'26) |
LOW |
| JNJ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
LOW |
| JNJ |
Return |
5-day cumulative residual |
-0.3% (FADE) |
A beat + modest raise likely sparks a small day-1 pop, but the raise is largely FX/beat flow-through rather than an underlying step-up. Out-period math is capped by known 2H headwinds (China VBP in EP, continued STELARA erosion, heavy 1H launch investment/tariff margin pressure) and soft MedTech, so consensus out-quarters get trimmed even after a beat. With the stock up ~22% YTD, near ATH (~$267 on 7/7) and already down 5% into the print, profit-taking and a demanding bar drive a fade back toward flat. |
LOW |